stiripentol

Ligand id: 5469

Name: stiripentol

Structure and Physico-chemical Properties

2D Structure
Click here for structure editor
Calculated Physico-chemical Properties
Hydrogen bond acceptors 1
Hydrogen bond donors 1
Rotatable bonds 3
Topological polar surface area 38.69
Molecular weight 234.13
XLogP 2.88
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
May be used as an adjunct in the treatment of epilepsy. In particular, this drug is indicated for the treatment of severe myoclonic epilepsy in infancy (SMEI or Dravet's syndrome). FDA approval as a treatment for the siezures associated with Dravet's syndrome was granted in August 2018, with approval including children 2 years of age and older whose symptoms are inadequately controlled by clobazam.
Mechanism Of Action and Pharmacodynamic Effects
Stiripentol appears to increase inhibitory GABA transmission, by increasing the duration of opening of GABAA channels. It may also improve the effectiveness of other anticonvulsants.
External links